oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2021-20-1-141-148oncotomsk-1701Research ArticleОБЗОРЫREVIEWSЭВОЛЮЦИЯ ЛЕЧЕНИЯ РАКА БОЛЬШОГО СОСОЧКА ДВЕНАДЦАТИПЕРСТНОЙ КИШКИEVOLUTION OF TREATMENT OF CANCER OF THE MAJOR DUODENAL PAPILLAНазароваД. В.NazarovaD. V.

старший ординатор отделения реконструктивно-пластической хирургии Россия, 664035, г. Иркутск, ул. Фрунзе, 32

MD, Senior Resident of the Department of Reconstructive Surgery

32, Frunze Street, Irkutsk, 664035, Irkutsk, Russia

РасуловР. И.RasulovR. I.

доктор медицинских наук, профессор кафедры онкологии

SPIN-код: 3520-6049. Author ID (РИНЦ): 419107 Россия, 664049, г. Иркутск, м/р Юбилейный,100

MD, Professor, Department of Oncology

100, mkr. Yubileyniy, 664049, Irkutsk, Russia

gava2010@yandex.ruЗубринскийК. Г.ZubrinskyK. G.

врач отделения медицинской статистики Россия, 664035, г. Иркутск, ул. Фрунзе, 32

MD, Department of Medical Statistics

32, Frunze Street, Irkutsk, 664035, Irkutsk, Russia

СонголовГ. И.SogolovG. I.

кандидат медицинских наук, доцент кафедры топографической анатомии и оперативнойхирургии

SPIN-код: 4008-8488. AuthorID (РИНЦ): 627786 Россия, 664003, г. Иркутск, ул. Красного Восстания, 1

MD, Associate Professor, Department of Surgery and Topographic Anatomy

1, Krasnogo Vosstaniya Street, 664003, Irkutsk, Russia

ГБУЗ «Областной онкологический диспансер»РоссияIrkutsk Regional Cancer ClinicRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФРоссияDepartment of Oncology, Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationФГБОУ ВО «Иркутский государственный медицинский университет» МЗ РФРоссияIrkutsk State Medical UniversityRussian Federation202106032021201141148Copyright © Назарова Д.В., Расулов Р.И., Зубринский К.Г., Сонголов Г.И., 20212021Назарова Д.В., Расулов Р.И., Зубринский К.Г., Сонголов Г.И.Nazarova D.V., Rasulov R.I., Zubrinsky K.G., Sogolov G.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1701

Cancer of the major duodenal papilla is a rare disease with a reported population incidence of 6 per million. Endoscopic ultrasonography and intraductal ultrasonography are useful for diagnosing tumor  extension of the major duodenal papilla. However, there are no specific biochemical studies or tumor markers, and an algorithm for early diagnosis of cancer of the major duodenal papilla has not been developed. Pancreatoduodenal resection remains the main treatment method for patients with a resectable tumor. However, long-term outcomes of radical surgeries are not satisfactory, with the median survival rate of 52–113 months, and the 5-year survival rate of 30–78.8 %. The study of prognostic factors will allow the development of the effective schemes of radical treatment, a therapeutic algorithm that will inevitably increase life expectancy. Radical surgery should be integrated into multi-modal treatment. Of all the variety of prognostic factors, the morphological differentiation of the tumor is of interest. According to our data, the overall 5-year survival rate, the average life expectancy for pancreatobiliary and intestinal subtypes of cancer of the major duodenal papilla after expanded pancreatoduodenal resection, respectively, was 0 % versus 38.05 % and 9.3 ± 1.79 months versus 48.0 ± 7.69 months. An accurate morphological diagnosis is of paramount prognostic importance, since it can have therapeutic consequences; that is, morphologically oriented and specific (neo)adjuvant treatment corresponding to subtypes of cancer of the major duodenal papilla. Currently, a multi-modal approach in the treatment of cancer of the major duodenal papilla is under development. Data on the use of adjuvant therapy in the radical treatment regimen are contradictory. There are no randomized controlled trials for neoadjuvant treatment. Little attention is paid to complications of chemotherapy and radiation therapy in the neoadjuvant treatment option. According to our data, chemoembolization of the gastro-duodenal artery resulted in complications in 21.4 %, and external beam radiation therapy resulted in radiation-induced injuries in 25 %. NCC N and ESMO currently do not provide recommendations for (neo)adjuvant treatment of cancer of the major duodenal papilla.

рак большого сосочка двенадцатиперстной кишкинеоадъювантная и адъювантная терапиярадикальные хирургические вмешательстваcancer of the major duodenal papillaadjuvant treatmentneoadjuvant treatmentradical operationpancreatoduodenal resectionReferencesAhn D.H., Bekaii-Saab T. Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book. 2014: 112–5. doi: 10.14694/EdBook_AM.2014.34.112.Ahn D.H., Bekaii-Saab T. Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book. 2014: 112–5. doi: 10.14694/EdBook_AM.2014.34.112.Ishihara S., Horiguchi A., Miyakawa S., Endo I., Miyazaki M., Takada T. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci. 2016 Mar; 23(3): 149– 57. doi: 10.1002/jhbp.314.Ishihara S., Horiguchi A., Miyakawa S., Endo I., Miyazaki M., Takada T. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci. 2016 Mar; 23(3): 149– 57. doi: 10.1002/jhbp.314.Riall T.S., Cameron J.L., Lillemoe K.D., Winter J.M., Campbell K.A., Hruban R.H., Chang D., Yeo C.J. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006 Nov; 140(5): 764–72. doi: 10.1016/j.surg.2006.04.006.Riall T.S., Cameron J.L., Lillemoe K.D., Winter J.M., Campbell K.A., Hruban R.H., Chang D., Yeo C.J. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006 Nov; 140(5): 764–72. doi: 10.1016/j.surg.2006.04.006.Miyakawa S., Ishihara S., Horiguchi A., Takada T., Miyazaki M., Nagakawa T. Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009; 16(1): 1–7. doi: 10.1007/s00534-008-0015-0.Miyakawa S., Ishihara S., Horiguchi A., Takada T., Miyazaki M., Nagakawa T. Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009; 16(1): 1–7. doi: 10.1007/s00534-008-0015-0.Liu F., Cheng J.L., Cui J., Xu Z.Z., Fu Z., Liu J., Tian H. Surgical method choice and coincidence rate of pathological diagnoses in transduodenal ampullectomy: A retrospective case series study and review of the literature. World J Clin Cases. 2019 Mar 26; 7(6): 717–726. doi: 10.12998/wjcc.v7.i6.717.Liu F., Cheng J.L., Cui J., Xu Z.Z., Fu Z., Liu J., Tian H. Surgical method choice and coincidence rate of pathological diagnoses in transduodenal ampullectomy: A retrospective case series study and review of the literature. World J Clin Cases. 2019 Mar 26; 7(6): 717–726. doi: 10.12998/wjcc.v7.i6.717.Rattner D.W., Fernandez-del Castillo C., Brugge W.R., Warshaw A.L. Defining the criteria for local resection of ampullary neoplasms. Arch Surg. 1996 Apr; 131(4): 366–71. doi: 10.1001/archsurg.1996.01430160024003.Rattner D.W., Fernandez-del Castillo C., Brugge W.R., Warshaw A.L. Defining the criteria for local resection of ampullary neoplasms. Arch Surg. 1996 Apr; 131(4): 366–71. doi: 10.1001/archsurg.1996.01430160024003.Roggin K.K., Yeh J.J., Ferrone C.R., Riedel E., Gerdes H., Klimstra D.S., Jaques D.P., Brennan M.F. Limitations of ampullectomy in the treatment of nonfamilial ampullary neoplasms. Ann Surg Oncol. 2005; 12(12): 971–80. doi: 10.1245/ASO.2005.03.009.Roggin K.K., Yeh J.J., Ferrone C.R., Riedel E., Gerdes H., Klimstra D.S., Jaques D.P., Brennan M.F. Limitations of ampullectomy in the treatment of nonfamilial ampullary neoplasms. Ann Surg Oncol. 2005; 12(12): 971–80. doi: 10.1245/ASO.2005.03.009.Ceppa E.P., Burbridge R.A., Rialon K.L., Omotosho P.A., Emick D., Jowell P.S., Branch M.S., Pappas T.N. Endoscopic versus surgical ampullectomy: an algorithm to treat disease of the ampulla of Vater. Ann Surg. 2013 Feb; 257(2): 315–22. doi: 10.1097/SLA.0b013e318269d010.Ceppa E.P., Burbridge R.A., Rialon K.L., Omotosho P.A., Emick D., Jowell P.S., Branch M.S., Pappas T.N. Endoscopic versus surgical ampullectomy: an algorithm to treat disease of the ampulla of Vater. Ann Surg. 2013 Feb; 257(2): 315–22. doi: 10.1097/SLA.0b013e318269d010.Beger H.G., Treitschke F., Gansauge F., Harada N., Hiki N., Mattfeldt T. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg. 1999; 134(5): 526–32. doi: 10.1001/archsurg.134.5.526.Beger H.G., Treitschke F., Gansauge F., Harada N., Hiki N., Mattfeldt T. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg. 1999; 134(5): 526–32. doi: 10.1001/archsurg.134.5.526.Casaretto E., Andrada D.G., Granero L.E. Results of cephalic pancreaticoduodenectomy for ampullary carcinoma. Analysis of 18 consecutive cases. Acta Gastroenterol Latinoam. 2010 Mar; 40(1): 22–31.Casaretto E., Andrada D.G., Granero L.E. Results of cephalic pancreaticoduodenectomy for ampullary carcinoma. Analysis of 18 consecutive cases. Acta Gastroenterol Latinoam. 2010 Mar; 40(1): 22–31.Bourgouin S., Ewald J., Mancini J., Moutardier V., Delpero J.R., Le Treut Y.P. Disease-free survival following resection in non-ductal periampullary cancers: A retrospective multicenter analysis. Int J Surg. 2017; 42: 103–109. doi: 10.1016/j.ijsu.2017.04.051.Bourgouin S., Ewald J., Mancini J., Moutardier V., Delpero J.R., Le Treut Y.P. Disease-free survival following resection in non-ductal periampullary cancers: A retrospective multicenter analysis. Int J Surg. 2017; 42: 103–109. doi: 10.1016/j.ijsu.2017.04.051.Dorandeu A., Raoul J.L., Siriser F., Leclercq-Rioux N., Gosselin M., Martin E.D., Ramée M.P., Launois B. Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases. Gut. 1997 Mar; 40(3): 350–5. doi: 10.1136/gut.40.3.350.Dorandeu A., Raoul J.L., Siriser F., Leclercq-Rioux N., Gosselin M., Martin E.D., Ramée M.P., Launois B. Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases. Gut. 1997 Mar; 40(3): 350–5. doi: 10.1136/gut.40.3.350.Hsu H.P., Yang T.M., Hsieh Y.H., Shan Y.S., Lin P.W. Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol. 2007 Jan; 14(1): 50–60. doi: 10.1245/s10434-006-9136-3.Hsu H.P., Yang T.M., Hsieh Y.H., Shan Y.S., Lin P.W. Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol. 2007 Jan; 14(1): 50–60. doi: 10.1245/s10434-006-9136-3.Todoroki T., Koike N., Morishita Y., Kawamoto T., Ohkohchi N., Shoda J., Fukuda Y., Takahashi H. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol. 2003 Dec; 10(10): 1176–83. doi: 10.1245/aso.2003.07.512.Todoroki T., Koike N., Morishita Y., Kawamoto T., Ohkohchi N., Shoda J., Fukuda Y., Takahashi H. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol. 2003 Dec; 10(10): 1176–83. doi: 10.1245/aso.2003.07.512.O'Connell J.B., Maggard M.A., Manunga J.Jr., Tomlinson J.S., Reber H.A., Ko C.Y., Hines O.J. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol. 2008 Jul; 15(7): 1820–7. doi: 10.1245/s10434-008-9886-1.O'Connell J.B., Maggard M.A., Manunga J.Jr., Tomlinson J.S., Reber H.A., Ko C.Y., Hines O.J. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol. 2008 Jul; 15(7): 1820–7. doi: 10.1245/s10434-008-9886-1.Sudo T., Murakami Y., Uemura K., Hayashidani Y., Hashimoto Y., Ohge H., Shimamoto F., Sueda T. Prognostic impact of perineural invasion following pancreatoduodenectomy with lymphadenectomy for ampullary carcinoma. Dig Dis Sci. 2008 Aug; 53(8): 2281–6. doi: 10.1007/s10620-007-0117-6.Sudo T., Murakami Y., Uemura K., Hayashidani Y., Hashimoto Y., Ohge H., Shimamoto F., Sueda T. Prognostic impact of perineural invasion following pancreatoduodenectomy with lymphadenectomy for ampullary carcinoma. Dig Dis Sci. 2008 Aug; 53(8): 2281–6. doi: 10.1007/s10620-007-0117-6.Kim W.S., Choi D.W., Choi S.H., Heo J.S., You D.D., Lee H.G. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol. 2012 Mar; 105(3): 266–72. doi: 10.1002/jso.22090.Kim W.S., Choi D.W., Choi S.H., Heo J.S., You D.D., Lee H.G. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol. 2012 Mar; 105(3): 266–72. doi: 10.1002/jso.22090.Murakami T., Matsuyama R., Ueda M., Mochizuki Y., Homma Y., Kameda K., Yazawa K., Izumisawa Y., Fukushima T., Kamimukai N., Yoshida K., Kamiya N., Hoffman R.M., Endo I. High-Mobility Group Box 1 expression predicts survival of patients after resection of adenocarcinoma of the ampulla of Vater. World J Surg Oncol. 2019 Aug 9; 17(1): 140. doi: 10.1186/s12957-019-1675-8.Murakami T., Matsuyama R., Ueda M., Mochizuki Y., Homma Y., Kameda K., Yazawa K., Izumisawa Y., Fukushima T., Kamimukai N., Yoshida K., Kamiya N., Hoffman R.M., Endo I. High-Mobility Group Box 1 expression predicts survival of patients after resection of adenocarcinoma of the ampulla of Vater. World J Surg Oncol. 2019 Aug 9; 17(1): 140. doi: 10.1186/s12957-019-1675-8.Zimmermann C., Wolk S., Aust D.E., Meier F., Saeger H.D., Ehehalt F., Weitz J., Welsch T., Distler M. The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep. 2019; 9(1): 12676. doi: 10.1038/s41598-019-49179-w.Zimmermann C., Wolk S., Aust D.E., Meier F., Saeger H.D., Ehehalt F., Weitz J., Welsch T., Distler M. The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep. 2019; 9(1): 12676. doi: 10.1038/s41598-019-49179-w.Yamaguchi K., Enjoji M., Tsuneyoshi M. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol. 1991; 47(3): 148–54. doi: 10.1002/jso.2930470303.Yamaguchi K., Enjoji M., Tsuneyoshi M. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol. 1991; 47(3): 148–54. doi: 10.1002/jso.2930470303.Martin E.D. Anatomopathologie des tumeurs oddiennes. Les tumeurs oddiennes. Paris: Masson, 1978. 35–52.Martin E.D. Anatomopathologie des tumeurs oddiennes. Les tumeurs oddiennes. Paris: Masson, 1978. 35–52.Talbot I.C., Neoptolemos J.P., Shaw D.E., Carr-Locke D. The histopathology and staging of carcinoma of the ampulla of Vater. Histopathology. 1988 Feb; 12(2): 155–65. doi: 10.1111/j.1365-2559.1988.tb01926.x.Talbot I.C., Neoptolemos J.P., Shaw D.E., Carr-Locke D. The histopathology and staging of carcinoma of the ampulla of Vater. Histopathology. 1988 Feb; 12(2): 155–65. doi: 10.1111/j.1365-2559.1988.tb01926.x.Monson J.R., Donohue J.H., McEntee G.P., McIlrath D.C., van Heerden J.A., Shorter R.G., Nagorney D.M., Ilstrup D.M. Radical resection for carcinoma of the ampulla of Vater. Arch Surg. 1991 Mar; 126(3): 353–7. doi: 10.1001/archsurg.1991.01410270099016.Monson J.R., Donohue J.H., McEntee G.P., McIlrath D.C., van Heerden J.A., Shorter R.G., Nagorney D.M., Ilstrup D.M. Radical resection for carcinoma of the ampulla of Vater. Arch Surg. 1991 Mar; 126(3): 353–7. doi: 10.1001/archsurg.1991.01410270099016.Dawson P.J., Connolly M.M. Influence of site of origin and mucin production on survival in ampullary carcinoma. Ann Surg. 1989 Aug; 210(2): 1739. doi: 10.1097/00000658-198908000-00006.Dawson P.J., Connolly M.M. Influence of site of origin and mucin production on survival in ampullary carcinoma. Ann Surg. 1989 Aug; 210(2): 1739. doi: 10.1097/00000658-198908000-00006.Kozuka S., Tsubone M., Yamaguchi A., Hachisuka K.Adenomatous residue in cancerous papilla of Vater. Gut. 1981 Dec; 22(12): 10314. doi: 10.1136/gut.22.12.1031.Kozuka S., Tsubone M., Yamaguchi A., Hachisuka K.Adenomatous residue in cancerous papilla of Vater. Gut. 1981 Dec; 22(12): 10314. doi: 10.1136/gut.22.12.1031.Kamisawa T., Fukayama M., Koike M., Tabata I., Egawa N., Isawa T., Okamoto A., Hayashi Y. Carcinoma of the ampulla of Vater: expression of cancer-associated antigens inversely correlated with prognosis. Am J Gastroenterol. 1988 Oct; 83(10): 111823.Kamisawa T., Fukayama M., Koike M., Tabata I., Egawa N., Isawa T., Okamoto A., Hayashi Y. Carcinoma of the ampulla of Vater: expression of cancer-associated antigens inversely correlated with prognosis. Am J Gastroenterol. 1988 Oct; 83(10): 111823.Willett C.G., Warshaw A.L., Convery K., Compton C.C. Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. Surg Gynecol Obstet. 1993 Jan; 176(1): 338.Willett C.G., Warshaw A.L., Convery K., Compton C.C. Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. Surg Gynecol Obstet. 1993 Jan; 176(1): 338.Willett C.G., Lewandrowski K., Warshaw A.L., Efird J., Compton C.C. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg. 1993 Feb; 217(2): 1448. doi: 10.1097/00000658-199302000-00008.Willett C.G., Lewandrowski K., Warshaw A.L., Efird J., Compton C.C. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg. 1993 Feb; 217(2): 1448. doi: 10.1097/00000658-199302000-00008.Nakao A., Harada A., Nonami T., Kishimoto W., Takeda S., Ito K., Takagi H. Prognosis of cancer of the duodenal papilla of Vater in relation to clinicopathological tumor extension. Hepatogastroenterology. 1994 Feb; 41(1): 738.Nakao A., Harada A., Nonami T., Kishimoto W., Takeda S., Ito K., Takagi H. Prognosis of cancer of the duodenal papilla of Vater in relation to clinicopathological tumor extension. Hepatogastroenterology. 1994 Feb; 41(1): 738.Allema J.H., Reinders M.E., van Gulik T.M., van Leeuwen D.J., Verbeek P.C., de Wit L.T., Gouma D.J. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery. 1995 Mar; 117(3): 24753. doi: 10.1016/s0039-6060(05)80197-7.Allema J.H., Reinders M.E., van Gulik T.M., van Leeuwen D.J., Verbeek P.C., de Wit L.T., Gouma D.J. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery. 1995 Mar; 117(3): 24753. doi: 10.1016/s0039-6060(05)80197-7.Su C.H., Shyr Y.M., Lui W.Y., P'eng F.K. Factors affecting morbidity, mortality and survival after pancreaticoduodenectomy for carcinoma of the ampulla of Vater. Hepatogastroenterology. 1999 May-Jun; 46(27): 19739.Su C.H., Shyr Y.M., Lui W.Y., P'eng F.K. Factors affecting morbidity, mortality and survival after pancreaticoduodenectomy for carcinoma of the ampulla of Vater. Hepatogastroenterology. 1999 May-Jun; 46(27): 19739.Lee J.H., Whittington R., Williams N.N., Berry M.F., Vaughn D.J., Haller D.G., Rosato E.F. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys. 2000 Jul 1; 47(4): 94553. doi: 10.1016/s0360-3016(00)00537-x.Lee J.H., Whittington R., Williams N.N., Berry M.F., Vaughn D.J., Haller D.G., Rosato E.F. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys. 2000 Jul 1; 47(4): 94553. doi: 10.1016/s0360-3016(00)00537-x.Talamini M.A., Moesinger R.C., Pitt H.A., Sohn T.A., Hruban R.H., Lillemoe K.D., Yeo C.J., Cameron J.L. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg. 1997 May; 225(5): 5909; discussion 599600. doi: 10.1097/00000658-199705000-00015.Talamini M.A., Moesinger R.C., Pitt H.A., Sohn T.A., Hruban R.H., Lillemoe K.D., Yeo C.J., Cameron J.L. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg. 1997 May; 225(5): 5909; discussion 599600. doi: 10.1097/00000658-199705000-00015.Shirai Y., Tsukada K., Ohtani T., Hatakeyama K. Carcinoma of the ampulla of Vater: is radical lymphadenectomy beneficial to patients with nodal disease? J Surg Oncol. 1996 Mar; 61(3): 1904. doi: 10.1002/(SICI)1096-9098(199603)61:3<190::AID-JSO5>3.0.CO;2-6.Shirai Y., Tsukada K., Ohtani T., Hatakeyama K. Carcinoma of the ampulla of Vater: is radical lymphadenectomy beneficial to patients with nodal disease? J Surg Oncol. 1996 Mar; 61(3): 1904. doi: 10.1002/(SICI)1096-9098(199603)61:3<190::AID-JSO5>3.0.CO;2-6.Brown K.M., Tompkins A.J., Yong S., Aranha G.V., Shoup M. Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. Arch Surg. 2005 Jun; 140(6): 52932; discussion 532-3. doi: 10.1001/archsurg.140.6.529.Brown K.M., Tompkins A.J., Yong S., Aranha G.V., Shoup M. Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. Arch Surg. 2005 Jun; 140(6): 52932; discussion 532-3. doi: 10.1001/archsurg.140.6.529.Narang A.K., Miller R.C., Hsu C.C., Bhatia S., Pawlik T.M., Laheru D., Hruban R.H., Zhou J., Winter J.M., Haddock M.G., Donohue J.H., Schulick R.D., Wolfgang C.L., Cameron J.L., Herman J.M. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol. 2011 Sep 28; 6: 126. doi: 10.1186/1748-717X-6-126.Narang A.K., Miller R.C., Hsu C.C., Bhatia S., Pawlik T.M., Laheru D., Hruban R.H., Zhou J., Winter J.M., Haddock M.G., Donohue J.H., Schulick R.D., Wolfgang C.L., Cameron J.L., Herman J.M. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol. 2011 Sep 28; 6: 126. doi: 10.1186/1748-717X-6-126.Kawaida H., Kono H., Amemiya H., Hosomura N., Watanabe M., Saito R., Maruyama S., Shimizu H., Furuya S., Akaike H., Kawaguchi Y., Sudo M., Matusda M., Itakura J., Shindo H., Takahashi E.I., Takano S., Fukasawa M., Satou T., Nakazawa T., Enomoto N., Fujii H., Ichikawa D. Stratification of Prognosis in Patients With Ampullary Carcinoma After Surgery by Preoperative Platelet-to-lymphocyte Ratio and Conventional Tumor Markers. Anticancer Res. 2019 Dec; 39(12): 69236929. doi: 10.21873/anticanres.13913.Kawaida H., Kono H., Amemiya H., Hosomura N., Watanabe M., Saito R., Maruyama S., Shimizu H., Furuya S., Akaike H., Kawaguchi Y., Sudo M., Matusda M., Itakura J., Shindo H., Takahashi E.I., Takano S., Fukasawa M., Satou T., Nakazawa T., Enomoto N., Fujii H., Ichikawa D. Stratification of Prognosis in Patients With Ampullary Carcinoma After Surgery by Preoperative Platelet-to-lymphocyte Ratio and Conventional Tumor Markers. Anticancer Res. 2019 Dec; 39(12): 69236929. doi: 10.21873/anticanres.13913.Kimura W., Futakawa N., Yamagata S., Wada Y., Kuroda A., Muto T., Esaki Y. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res. 1994 Feb; 85(2): 1616. doi: 10.1111/j.1349-7006.1994.tb02077.x.Kimura W., Futakawa N., Yamagata S., Wada Y., Kuroda A., Muto T., Esaki Y. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res. 1994 Feb; 85(2): 1616. doi: 10.1111/j.1349-7006.1994.tb02077.x.Albores-Saavedra J., Henson D.E., Klimstra D.S. Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Atlas of tumor pathology. 2000; 27: 259316.Albores-Saavedra J., Henson D.E., Klimstra D.S. Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Atlas of tumor pathology. 2000; 27: 259316.Radojkovic M., Stojanovic M., Radojković D., Jeremic L., Mihailovic D., Ilic I. Histopathologic differentiation as a prognostic factor in patients with carcinoma of the hepatopancreatic ampulla of Vater. J Int Med Res. 2018 Nov; 46(11): 46344639. doi: 10.1177/0300060518786920.Radojkovic M., Stojanovic M., Radojković D., Jeremic L., Mihailovic D., Ilic I. Histopathologic differentiation as a prognostic factor in patients with carcinoma of the hepatopancreatic ampulla of Vater. J Int Med Res. 2018 Nov; 46(11): 46344639. doi: 10.1177/0300060518786920.Kohler I., Jacob D., Budzies J., Lehmann A., Weichert W., Schulz S., Neuhaus P., Röcken C. Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications. Am J Clin Pathol. 2011 Feb; 135(2): 20211. doi: 10.1309/AJCPCTCUQSYI89YT.Kohler I., Jacob D., Budzies J., Lehmann A., Weichert W., Schulz S., Neuhaus P., Röcken C. Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications. Am J Clin Pathol. 2011 Feb; 135(2): 20211. doi: 10.1309/AJCPCTCUQSYI89YT.Westgaard A., Pomianowska E., Clausen O.P., Gladhaug I.P. Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies? Ann Surg Oncol. 2013 Feb; 20(2): 4309. doi: 10.1245/s10434-012-2603-0.Westgaard A., Pomianowska E., Clausen O.P., Gladhaug I.P. Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies? Ann Surg Oncol. 2013 Feb; 20(2): 4309. doi: 10.1245/s10434-012-2603-0.Asano E., Okano K., Oshima M., Kagawa S., Kushida Y., Munekage M., Hanazaki K., Watanabe J., Takada Y., Ikemoto T., Shimada M., Suzuki Y.; Shikoku Consortium of Surgical Research (SCSR). Phenotypic characterization and clinical outcome in ampullary adenocarcinoma. J Surg Oncol. 2016 Jul; 114(1): 11927. doi: 10.1002/jso.24274.Asano E., Okano K., Oshima M., Kagawa S., Kushida Y., Munekage M., Hanazaki K., Watanabe J., Takada Y., Ikemoto T., Shimada M., Suzuki Y.; Shikoku Consortium of Surgical Research (SCSR). Phenotypic characterization and clinical outcome in ampullary adenocarcinoma. J Surg Oncol. 2016 Jul; 114(1): 11927. doi: 10.1002/jso.24274.Bowitz Lothe I.M., Kleive D., Pomianowska E., Cvancarova M., Kure E., Dueland S., Gladhaug I.P., Labori K.J. Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy. Pancreatology. 2019 Mar; 19(2): 316324. doi: 10.1016/j.pan.2019.01.019.Bowitz Lothe I.M., Kleive D., Pomianowska E., Cvancarova M., Kure E., Dueland S., Gladhaug I.P., Labori K.J. Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy. Pancreatology. 2019 Mar; 19(2): 316324. doi: 10.1016/j.pan.2019.01.019.Nitschke P., Volk A., Welsch T., Hackl J., Reissfelder C., Rahbari M., Distler M., Saeger H.D., Weitz J., Rahbari N.N. Impact of Intraoperative Re-resection to Achieve R0 Status on Survival in Patients With Pancreatic Cancer: A Single-center Experience With 483 Patients. Ann Surg. 2017 Jun; 265(6): 12191225. doi: 10.1097/SLA.0000000000001808.Nitschke P., Volk A., Welsch T., Hackl J., Reissfelder C., Rahbari M., Distler M., Saeger H.D., Weitz J., Rahbari N.N. Impact of Intraoperative Re-resection to Achieve R0 Status on Survival in Patients With Pancreatic Cancer: A Single-center Experience With 483 Patients. Ann Surg. 2017 Jun; 265(6): 12191225. doi: 10.1097/SLA.0000000000001808.Schiergens T.S., Reu S., Neumann J., Renz B.W., Niess H., Boeck S., Heinemann V., Bruns C.J., Jauch K.W., Kleespies A. Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. Surgery. 2015 Jul; 158(1): 15161. doi: 10.1016/j.surg.2015.02.001.Schiergens T.S., Reu S., Neumann J., Renz B.W., Niess H., Boeck S., Heinemann V., Bruns C.J., Jauch K.W., Kleespies A. Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. Surgery. 2015 Jul; 158(1): 15161. doi: 10.1016/j.surg.2015.02.001.Neoptolemos J.P., Moore M.J., Cox T.F., Valle J.W., Palmer D.H., Mcdonald A., Carter R., Tebbutt N.C., Dervenis C., Smith D., Glimelius B., Coxon F.Y., Lacaine F., Middleton M.R., Ghaneh P., Bassi C., Halloran C., Olah A., Rawcliffe C.L., Büchler M.W. Ampullary cancer ESPAC-3 (v2) trial: a multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater. J Clin Oncol. 2016; 29: LBA4006.Neoptolemos J.P., Moore M.J., Cox T.F., Valle J.W., Palmer D.H., Mcdonald A., Carter R., Tebbutt N.C., Dervenis C., Smith D., Glimelius B., Coxon F.Y., Lacaine F., Middleton M.R., Ghaneh P., Bassi C., Halloran C., Olah A., Rawcliffe C.L., Büchler M.W. Ampullary cancer ESPAC-3 (v2) trial: a multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater. J Clin Oncol. 2016; 29: LBA4006.Klinkenbijl J.H., Jeekel J., Sahmoud T., van Pel R., Couvreur M.L., Veenhof C.H., Arnaud J.P., Gonzalez D.G., de Wit L.T., Hennipman A., Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999 Dec; 230(6): 77682; discussion 782-4. doi: 10.1097/00000658-199912000-00006.Klinkenbijl J.H., Jeekel J., Sahmoud T., van Pel R., Couvreur M.L., Veenhof C.H., Arnaud J.P., Gonzalez D.G., de Wit L.T., Hennipman A., Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999 Dec; 230(6): 77682; discussion 782-4. doi: 10.1097/00000658-199912000-00006.Takada T., Amano H., Yasuda H., Nimura Y., Matsushiro T., Kato H., Nagakawa T., Nakayama T.; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002 Oct 15; 95(8): 168595. doi: 10.1002/cncr.10831. PMID: 12365016.Takada T., Amano H., Yasuda H., Nimura Y., Matsushiro T., Kato H., Nagakawa T., Nakayama T.; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002 Oct 15; 95(8): 168595. doi: 10.1002/cncr.10831. PMID: 12365016.Mehta V.K., Fisher G.A., Ford J.M., Poen J.C., Vierra M.A., Oberhelman H.A., Bastidas A.J.Adjuvant chemoradiotherapy for «unfavorable» carcinoma of the ampulla of Vater: preliminary report. Arch Surg. 2001 Jan; 136(1): 659. doi: 10.1001/archsurg.136.1.65.Mehta V.K., Fisher G.A., Ford J.M., Poen J.C., Vierra M.A., Oberhelman H.A., Bastidas A.J.Adjuvant chemoradiotherapy for «unfavorable» carcinoma of the ampulla of Vater: preliminary report. Arch Surg. 2001 Jan; 136(1): 659. doi: 10.1001/archsurg.136.1.65.Bhatia S., Miller R.C., Haddock M.G., Donohue J.H., Krishnan S. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006 Oct 1; 66(2): 5149. doi: 10.1016/j.ijrobp.2006.04.018.Bhatia S., Miller R.C., Haddock M.G., Donohue J.H., Krishnan S. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006 Oct 1; 66(2): 5149. doi: 10.1016/j.ijrobp.2006.04.018.Palta M., Patel P., Broadwater G., Willett C., Pepek J., Tyler D., Zafar S.Y., Uronis H., Hurwitz H., White R., Czito B. Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. Ann Surg Oncol. 2012 May; 19(5): 153540. doi: 10.1245/s10434-011-2117-1.Palta M., Patel P., Broadwater G., Willett C., Pepek J., Tyler D., Zafar S.Y., Uronis H., Hurwitz H., White R., Czito B. Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. Ann Surg Oncol. 2012 May; 19(5): 153540. doi: 10.1245/s10434-011-2117-1.Ha H.R., Oh D.Y., Kim T.Y., Lee K., Kim K., Lee K.H., Han S.W., Chie E.K., Jang J.Y., Im S.A., Kim T.Y., Kim S.W., Bang Y.J. Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. PLoS One. 2016 Mar 14; 11(3): e0151406. doi: 10.1371/journal.pone.0151406.Ha H.R., Oh D.Y., Kim T.Y., Lee K., Kim K., Lee K.H., Han S.W., Chie E.K., Jang J.Y., Im S.A., Kim T.Y., Kim S.W., Bang Y.J. Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. PLoS One. 2016 Mar 14; 11(3): e0151406. doi: 10.1371/journal.pone.0151406.Kwon J., Kim B.H., Kim K., Chie E.K., Ha S.W. Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer: A Systematic Review and Meta-analysis. Ann Surg. 2015 Jul; 262(1): 4752. doi: 10.1097/SLA.0000000000001182.Kwon J., Kim B.H., Kim K., Chie E.K., Ha S.W. Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer: A Systematic Review and Meta-analysis. Ann Surg. 2015 Jul; 262(1): 4752. doi: 10.1097/SLA.0000000000001182.Nassour I., Hynan L.S., Christie A., Minter R.M., Yopp A.C., Choti M.A., Mansour J.C., Porembka M.R., Wang S.C. Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study. J Gastrointest Surg. 2018 Apr; 22(4): 695702. doi: 10.1007/s11605-017-3624-6.Nassour I., Hynan L.S., Christie A., Minter R.M., Yopp A.C., Choti M.A., Mansour J.C., Porembka M.R., Wang S.C. Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study. J Gastrointest Surg. 2018 Apr; 22(4): 695702. doi: 10.1007/s11605-017-3624-6.Primrose J.N., Fox R.P., Palmer D.H., Malik H.Z., Prasad R., Mirza D., Anthony A., Corrie P., Falk S., Finch-Jones M., Wasan H., Ross P., Wall L., Wadsley J., Evans J.T.R., Stocken D., Praseedom R., Ma Y.T., Davidson B., Neoptolemos J.P., Iveson T., Raftery J., Zhu S., Cunningham D., Garden O.J., Stubbs C., Valle J.W., Bridgewater J.; BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019 May; 20(5): 663673. doi: 10.1016/S1470-2045(18)30915-X.Primrose J.N., Fox R.P., Palmer D.H., Malik H.Z., Prasad R., Mirza D., Anthony A., Corrie P., Falk S., Finch-Jones M., Wasan H., Ross P., Wall L., Wadsley J., Evans J.T.R., Stocken D., Praseedom R., Ma Y.T., Davidson B., Neoptolemos J.P., Iveson T., Raftery J., Zhu S., Cunningham D., Garden O.J., Stubbs C., Valle J.W., Bridgewater J.; BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019 May; 20(5): 663673. doi: 10.1016/S1470-2045(18)30915-X.Yeung R.S., Weese J.L., Hoffman J.P., Solin L.J., Paul A.R., Engstrom P.F., Litwin S., Kowalyshyn M.J., Eisenberg B.L. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer. 1993 Oct 1; 72(7): 212433. doi: 10.1002/1097-0142(19931001)72:7<2124::aidcncr2820720711>3.0.co;2-c.Yeung R.S., Weese J.L., Hoffman J.P., Solin L.J., Paul A.R., Engstrom P.F., Litwin S., Kowalyshyn M.J., Eisenberg B.L. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer. 1993 Oct 1; 72(7): 212433. doi: 10.1002/1097-0142(19931001)72:7<2124::aidcncr2820720711>3.0.co;2-c.Hoffman J.P., Cooper H.S., Young N.A., Pendurthi T.K. Preoperative chemotherapy of chemoradiotherapy for the treatment of adenocarcinoma of the pancreas and ampulla of Vater. J Hepatobiliary Pancreat Surg. 1998; 5(3): 2514. doi: 10.1007/s005340050042.Hoffman J.P., Cooper H.S., Young N.A., Pendurthi T.K. Preoperative chemotherapy of chemoradiotherapy for the treatment of adenocarcinoma of the pancreas and ampulla of Vater. J Hepatobiliary Pancreat Surg. 1998; 5(3): 2514. doi: 10.1007/s005340050042.Cloyd J.M., Wang H., Overman M., Zhao J., Denbo J., Prakash L., Kim M.P., Shroff R., Javle M., Varadhachary G.R., Fogelman D., Wolff R.A., Koay E.J., Das P., Maitra A., Aloia T.A., Vauthey J.N., Fleming J.B., Lee J.E., Katz M.H.G. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7): 20312039. doi: 10.1245/s10434-017-5777-7.Cloyd J.M., Wang H., Overman M., Zhao J., Denbo J., Prakash L., Kim M.P., Shroff R., Javle M., Varadhachary G.R., Fogelman D., Wolff R.A., Koay E.J., Das P., Maitra A., Aloia T.A., Vauthey J.N., Fleming J.B., Lee J.E., Katz M.H.G. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7): 20312039. doi: 10.1245/s10434-017-5777-7.Yamashita S., Overman M.J., Wang H., Zhao J., Okuno M., Goumard C., Tzeng C.W., Kim M., Fleming J.B., Vauthey J.N., Katz M.H., Lee J.E., Conrad C. Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. Ann Surg Oncol. 2017 Dec; 24(13): 39543963. doi: 10.1245/s10434-017-6098-6.Yamashita S., Overman M.J., Wang H., Zhao J., Okuno M., Goumard C., Tzeng C.W., Kim M., Fleming J.B., Vauthey J.N., Katz M.H., Lee J.E., Conrad C. Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. Ann Surg Oncol. 2017 Dec; 24(13): 39543963. doi: 10.1245/s10434-017-6098-6.

The authors declare that there are no conflicts of interest present.